Combined Human Milk Oligosaccharides (HMOs) and Probiotics Intervention for Children With Autism
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05151601|
Recruitment Status : Active, not recruiting
First Posted : December 9, 2021
Last Update Posted : February 15, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Autism Spectrum Disorder Neurodevelopmental Disorders Anxiety||Dietary Supplement: Experimental Other: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||
Participants will be recruited into a two-phase project. Phase 1A: an 8-week double-blinded, placebo-controlled, randomised trial. Participants child will be randomised to one of groups 1) treatment (HMOs/Probiotic group) or 2) control group (placebo product).
Phase 1B: is an 8-week open-label trial. All children who successfully complete phase 1A will be recruited into phase 1B. All participants in phase 1B will receive the treatment product (HMOs/probiotics).
Follow up will occur at week 8 and week 17.
|Masking:||None (Open Label)|
|Official Title:||The Effect of a Combination of Human Milk Oligosaccharides (HMOs) and Probiotics on Behavioural Change in Children With Autism Spectrum Disorder (ASD).|
|Actual Study Start Date :||May 17, 2022|
|Estimated Primary Completion Date :||April 30, 2023|
|Estimated Study Completion Date :||December 31, 2023|
Experimental: HMOs + Probiotics
Dosing: A total daily dose of 2 x sachets (6g/day)
Product Comprised of:
Mode of administration: oral.
Dietary Supplement: Experimental
2 x sachets per day
Placebo Comparator: Placebo
Dosing: A total daily dose of 2 x sachets (6g/day)u (8 weeks of phase 1A). Product: powdered maltodextrin. Mode of administration: oral.
2 x sachets per day
- Behaviour change [ Time Frame: Baseline, Phase IA midpoint (week 4) and post-Phase 1A(week 8/9), post-Phase 1B (week 17/18) ]Changes in behavioural symptoms as measured by the Irritability sub-scale of the Aberrant Behavior Checklist - Community (Version 2) (I-ABC). The ABC 58-item parent-rated questionnaire and consists of five subscales, including: 1) irritability (15 items); 2) lethargy/social withdrawal (16 items); 3) stereotypic behaviour (7 items); 4) hyperactivity/noncompliance (16 items); and 5) inappropriate speech (4 items). Each item is scored as 0=never a problem, 1=slight problem, 2=moderately serious problem, or 3=severe problem. The score range is 0-174, with a higher score indicating greater severity or difficulties.
- Behaviour Change [ Time Frame: Baseline, Phase 1A midpoint (week 4) and post-Phase 1A (week 8/9) ]Changes in behavioural symptoms as measured by the Home Situations Questionnaire - Autism Spectrum Disorder (HSQ-ASD). The HSQ-ASD is a 24-item, parent-rated measure of non compliant behaviour in children with ASD. The scale yields per-item mean scores of 0 to 9, with higher scores indicating greater noncompliance.
- Behaviour Change [ Time Frame: Baseline and post-Phase 1A (week 8/9) ]Changes in parent/guardian targeted behaviours as measured by the Parent Targeted Symptom Visual Analogue Scale (PTSVAS). The PTSVAS tool requests parents/guardians report their top three (3) target behaviours (behaviours of concern) on a Visual Analogue Scale (VAS). The VAS is a horizontal line of 100mm in length, with each end defined as the extreme limits of the behaviour of concern ("best" to "worst"), to be measured from left to right. The parents will score the behaviour by placing a mark on the VAS at baseline and post-intervention. Each mark will be measured on the scale of 0-100mm and the change from baseline to post-intervention noted.
- Change in GI Symptom Severity [ Time Frame: Baseline and post-Phase 1A (week 8/9) ]Change in GI symptom severity as measured by the 6-item gastrointestinal severity index (6-GSI). The 6-GSI assesses each GI symptom using a Likert scale of 0-2 (0 = nil/mild/infrequent; 1 = moderate/occasional; 2 = severe/frequent). Score range 0-12. Mild GI issues are defined as a score of under three and moderate or severe GI issues defined as a score of three or above.
- Change in the Gut Microbiome [ Time Frame: Baseline and post-Phase 1A (week 8/9) ]This is an explorative outcome to compare and characterise changes in gut (stool) micorbiome between treatment groups. Change or trends (diversity, bacterial species, metabolite potential) in the gut microbiome as analysed using stool shotgun metagenomic sequencing.
- Change in Anxiety Levels [ Time Frame: Baseline and post-Phase 1A (week 8/9) ]Change in anxiety levels as measured by the Parent Rated Anxiety Scale - Autism Spectrum Disorder (PRAS-ASD) questionnaire. This is a 25-item tool using a Likert scale of 0-3 (0=none; 1=mild; 2=moderate; 3=severe). Score range 0-75, with higher scores indicating greater levels of anxiety.
- Change in Quality of Life [ Time Frame: Baseline and post-Phase 1A (week 8/9) ]Quality of life (QoL) measured by the Quality of life Autism (QoLA) questionnaire. The QoLA is a 48-item questionnaire divided into 2 subsets (Part A and Part B). The QoLA utilises a 5-point scale (0-4). Possible scores range from 48-240, with higher scores equating to higher perceived QoL.
- Change in Stool Consistency [ Time Frame: Baseline, Phase A1 midpoint (week 4), and post-Phase 1A (week 8/9), post-Phase 1B (week 17/18) . ]Change in Stool consistency as measured by the Bristol Stool Chart (BSC, paediatric version)
- Change in stool short chain fatty acids levels [ Time Frame: Baseline and post-Phase 1A (weeks 8/9) ]Change in stool short chain fatty acids levels as measured using gas chromatography with flame ionisation detection (GC-FID)
- Change in urinary serotonin concentration [ Time Frame: Baseline and post-Phase 1A (weeks 8/9) ]Change in concentrations of the urinary serotonin metabolite, 5-Hydroxyindoleacetic acid as measured using a double solvent front extraction, followed by reversed phase High Performance Liquid Chromatography (HPLC) with electrochemical detection (ECD)
- Change in salivary cortisol levels [ Time Frame: Baseline and post-Phase 1A (weeks 8/9) ]Change to salivary cortisol levels as measured using the Elecsys® Cortisol II assay
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||5 Years to 12 Years (Child)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Aged 5.00 years to 12.99 years.
- A confirmed diagnosis of ASD or Pervasive Developmental Disorders (PDD) including autistic disorder, Asperger's disorder (AS); PDD not otherwise specified (PDD-NOS); and atypical autism.
- Organic GI disorders such as inflammatory bowel disease, coeliac disease, eosinophilic disorders, or current infection of the GI tract.
- Bowel surgery or short bowel syndrome
- Participants who have a diagnosed cow milk protein allergy.
Participants who suffer from the conditions listed below or who are taking any of the following medications or supplements:
- antibiotics or antifungals in the last two months
- probiotic supplements in the last two months
- immunocompromised or severely ill
- genetic disorders (e.g. Fragile X Syndrome)
- chronic health conditions such as diabetes, heart disease or an eating disorder.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05151601
|University of Queensland, Child Health Research Centre|
|Brisbane, Queensland, Australia, 4001|
|Principal Investigator:||Peter SW Davies, PhD||The University of Queensland|
|Responsible Party:||The University of Queensland|
|Other Study ID Numbers:||
|First Posted:||December 9, 2021 Key Record Dates|
|Last Update Posted:||February 15, 2023|
|Last Verified:||February 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Plan Description:||IPD is the intellectual property of the funding industry partner.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Autism Spectrum Disorder
Child Development Disorders, Pervasive